|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: XRCC6 |
Gene summary for XRCC6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | XRCC6 | Gene ID | 2547 |
| Gene name | X-ray repair cross complementing 6 | |
| Gene Alias | CTC75 | |
| Cytomap | 22q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | A0A024R1N4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2547 | XRCC6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.53e-16 | 4.29e-01 | 0.0155 |
| 2547 | XRCC6 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.44e-12 | 6.64e-01 | -0.1808 |
| 2547 | XRCC6 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.19e-20 | 9.71e-01 | -0.0811 |
| 2547 | XRCC6 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.08e-08 | 5.19e-01 | -0.1088 |
| 2547 | XRCC6 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.52e-25 | 7.70e-01 | -0.1954 |
| 2547 | XRCC6 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.78e-07 | 1.06e+00 | -0.2602 |
| 2547 | XRCC6 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.08e-04 | 8.22e-01 | -0.2196 |
| 2547 | XRCC6 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.24e-14 | 8.11e-01 | -0.1207 |
| 2547 | XRCC6 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.74e-10 | 8.30e-01 | -0.1526 |
| 2547 | XRCC6 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.39e-32 | 9.71e-01 | -0.1464 |
| 2547 | XRCC6 | HTA11_866_2000001011 | Human | Colorectum | AD | 5.86e-09 | 5.09e-01 | -0.1001 |
| 2547 | XRCC6 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.01e-30 | 1.23e+00 | -0.059 |
| 2547 | XRCC6 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.64e-07 | 8.84e-01 | -0.1706 |
| 2547 | XRCC6 | HTA11_5212_2000001011 | Human | Colorectum | AD | 9.94e-08 | 6.16e-01 | -0.2061 |
| 2547 | XRCC6 | HTA11_5216_2000001011 | Human | Colorectum | SER | 7.26e-06 | 7.62e-01 | -0.1462 |
| 2547 | XRCC6 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.14e-12 | 7.98e-01 | -0.0842 |
| 2547 | XRCC6 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.08e-02 | 4.53e-01 | -0.0179 |
| 2547 | XRCC6 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.95e-31 | 9.72e-01 | 0.096 |
| 2547 | XRCC6 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.23e-07 | 9.03e-01 | 0.0446 |
| 2547 | XRCC6 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.59e-07 | 6.70e-01 | 0.0528 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00028311 | Liver | Cirrhotic | regulation of response to biotic stimulus | 101/4634 | 327/18723 | 6.58e-03 | 3.25e-02 | 101 |
| GO:004586011 | Liver | Cirrhotic | positive regulation of protein kinase activity | 117/4634 | 386/18723 | 7.07e-03 | 3.41e-02 | 117 |
| GO:006219722 | Liver | HCC | cellular response to chemical stress | 216/7958 | 337/18723 | 6.86e-16 | 5.44e-14 | 216 |
| GO:000072311 | Liver | HCC | telomere maintenance | 85/7958 | 131/18723 | 1.86e-07 | 3.40e-06 | 85 |
| GO:007121421 | Liver | HCC | cellular response to abiotic stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:010400421 | Liver | HCC | cellular response to environmental stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:001021221 | Liver | HCC | response to ionizing radiation | 89/7958 | 148/18723 | 1.10e-05 | 1.26e-04 | 89 |
| GO:007147921 | Liver | HCC | cellular response to ionizing radiation | 47/7958 | 72/18723 | 7.95e-05 | 7.07e-04 | 47 |
| GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
| GO:00714782 | Liver | HCC | cellular response to radiation | 104/7958 | 186/18723 | 1.48e-04 | 1.19e-03 | 104 |
| GO:00069702 | Liver | HCC | response to osmotic stress | 52/7958 | 84/18723 | 2.58e-04 | 1.92e-03 | 52 |
| GO:00103321 | Liver | HCC | response to gamma radiation | 37/7958 | 56/18723 | 3.13e-04 | 2.22e-03 | 37 |
| GO:00714802 | Liver | HCC | cellular response to gamma radiation | 23/7958 | 31/18723 | 3.47e-04 | 2.42e-03 | 23 |
| GO:0071474 | Liver | HCC | cellular hyperosmotic response | 13/7958 | 15/18723 | 5.67e-04 | 3.61e-03 | 13 |
| GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
| GO:00714701 | Liver | HCC | cellular response to osmotic stress | 28/7958 | 41/18723 | 7.54e-04 | 4.55e-03 | 28 |
| GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
| GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
| GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
| GO:00322001 | Liver | HCC | telomere organization | 86/7958 | 159/18723 | 2.06e-03 | 1.04e-02 | 86 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| XRCC6 | SNV | Missense_Mutation | rs765303000 | c.344G>A | p.Arg115Gln | p.R115Q | P12956 | protein_coding | tolerated(0.15) | benign(0.121) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| XRCC6 | SNV | Missense_Mutation | c.31N>C | p.Glu11Gln | p.E11Q | P12956 | protein_coding | tolerated(0.1) | benign(0.043) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| XRCC6 | SNV | Missense_Mutation | c.160N>A | p.Glu54Lys | p.E54K | P12956 | protein_coding | deleterious(0.04) | benign(0.127) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| XRCC6 | SNV | Missense_Mutation | c.492N>C | p.Lys164Asn | p.K164N | P12956 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| XRCC6 | SNV | Missense_Mutation | c.882A>T | p.Glu294Asp | p.E294D | P12956 | protein_coding | deleterious(0.02) | possibly_damaging(0.677) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| XRCC6 | SNV | Missense_Mutation | c.1715N>T | p.Thr572Met | p.T572M | P12956 | protein_coding | deleterious(0.03) | benign(0.194) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| XRCC6 | SNV | Missense_Mutation | novel | c.535N>C | p.Asp179His | p.D179H | P12956 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| XRCC6 | insertion | Nonsense_Mutation | novel | c.1675_1676insGGCGCCTGTAGTCCCAACTACCTGGGAG | p.Tyr559TrpfsTer4 | p.Y559Wfs*4 | P12956 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| XRCC6 | insertion | Nonsense_Mutation | novel | c.1786_1787insCTCCATCTCAAAAATGATACAG | p.Lys596ThrfsTer6 | p.K596Tfs*6 | P12956 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| XRCC6 | SNV | Missense_Mutation | novel | c.1366N>G | p.Pro456Ala | p.P456A | P12956 | protein_coding | tolerated(0.53) | benign(0.018) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |